Our Managing Director Tilmann Bur was interviewed by ISICEM at this year’s ISICEM Congress.
In the interview, he shares insights into the importance of strong partnerships and the role of innovation in anesthesia and intensive care medicine. To the interview on our LinkedIn page.
PAION Pharma nimmt BYFAVO® (Remimazolam) zum 1. September 2026 aus dem deutschen Markt zurück. Im Rahmen der Erstattungsbetragsverhandlungen mit dem GKV-Spitzenverband
We believe responsibility starts locally. That’s why we are delighted to support the Hap Ki Do European Championship 2026 on
You are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information